These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19734440)

  • 21. Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic hyperplasia.
    Carnevale FC; da Motta-Leal-Filho JM; Antunes AA; Baroni RH; Marcelino AS; Cerri LM; Yoshinaga EM; Cerri GG; Srougi M
    J Vasc Interv Radiol; 2013 Apr; 24(4):535-42. PubMed ID: 23434084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostatic hydroablation (Aquablation): A new effective ultrasound guided robotic waterjet ablative surgery for treatment of benign prostatic hyperplasia.
    Lim Ng K; Barber N
    Arch Esp Urol; 2019 Oct; 72(8):786-793. PubMed ID: 31579037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the Trade-Offs Men with Localized Prostate Cancer Make between the Risks and Benefits of Treatments: The COMPARE Study.
    Watson V; McCartan N; Krucien N; Abu V; Ikenwilo D; Emberton M; Ahmed HU
    J Urol; 2020 Aug; 204(2):273-280. PubMed ID: 31967521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating Patient Preferences in Benign Prostatic Hyperplasia Treatment Using Conjoint Analysis.
    Huffman PJ; Yin E; Cohen AJ
    Urology; 2022 Jun; 164():211-217. PubMed ID: 35063462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Men's health 2018: BPH, prostate cancer, erectile dysfunction, supplements.
    Chaitoff A; Killeen TC; Nielsen C
    Cleve Clin J Med; 2018 Nov; 85(11):871-880. PubMed ID: 30395524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment.
    Menges D; Piatti MC; Omlin A; Cathomas R; Benamran D; Fischer S; Iselin C; Küng M; Lorch A; Prause L; Rothermundt C; O'Meara Stern A; Zihler D; Lippuner M; Braun J; Cerny T; Puhan MA
    Eur Urol Open Sci; 2023 May; 51():26-38. PubMed ID: 37187724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment Preferences of Patients With Benign Prostatic Hyperplasia Before and After Using a Web-based Decision Aid.
    Lamers RED; van der Wijden FC; de Angst IB; de Vries M; Cuypers M; van Melick HHE; de Beij JS; Oerlemans DJAJ; van de Beek K; Bosch RJLHR; Kil PJM
    Urology; 2020 Mar; 137():138-145. PubMed ID: 31899227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient reactions to a program designed to facilitate patient participation in treatment decisions for benign prostatic hyperplasia.
    Barry MJ; Fowler FJ; Mulley AG; Henderson JV; Wennberg JE
    Med Care; 1995 Aug; 33(8):771-82. PubMed ID: 7543639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment.
    Janse S; Janssen E; Huwig T; Basu Roy U; Ferris A; Presley CJ; Bridges JFP
    Curr Med Res Opin; 2021 Apr; 37(4):643-653. PubMed ID: 33571024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changing Aspects of Male Sexual Functions Accompanying Treatment of Benign Prostatic Hyperplasia With Silodosin 8 mg Per Day.
    ; Cihan A; Kazaz İO; Yıldırım Ö; Deliktaş H; Ongün Ş; Gül Ü; Şahin B; Üre İ; Özkara H
    J Sex Med; 2020 Jun; 17(6):1094-1100. PubMed ID: 32217036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
    Marberger MJ
    Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostatic Artery Embolization Allows to Maintain Full Sexual Activity in Patients Suffering from Bothersome Lower Urinary Tracts Symptoms related to Benign Prostatic Hyperplasia.
    Marzano L; Thiounn N; Pereira H; Pellerin O; Dariane C; Del Giudice C; Amouyal G; Dean C; Sapoval M
    Cardiovasc Intervent Radiol; 2020 Aug; 43(8):1202-1207. PubMed ID: 32494835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
    Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L
    J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo-controlled study.
    Rosen RC; Roehrborn CG; Manyak MJ; Palacios-Moreno JM; Wilson TH; Lulic Z; Giuliano F
    Int J Clin Pract; 2019 Sep; 73(9):1-9. PubMed ID: 30317693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.